Clinical opportunities and challenges in targeting tumour dormancy
Authors:
- Thomas W. FlaigTFThomas W. Flaig
- Dan TheodorescuDTDan Theodorescu
- 27 November 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 10 (1) , 41-51
Abstract
The reactivation of cancer cells following a seemingly successful treatment of the primary tumour with initial therapies (such as tumour excision or systemic therapy) is a well-known phenomenon. This metastatic rebirth is preceded by an interlude, termed dormancy, when cancer sleeps undetected for periods that can last years or even decades. Discoveries over the past 10 years have revealed the therapeutic potential of prolonging dormancy for maintaining a clinically asymptomatic state, or the permanent clearance of dormant residual disseminated cancer cells to affect a 'cure'. Here, we provide an overview of the mechanisms of dormancy and use genitourinary cancers as models to demonstrate how dormancy principles could be exploited clinically. Data from these models have yielded promising therapeutic strategies to address dormancy as well as diagnostics that could enable clinicians to monitor the dormant state of cancer in patients. This Review also aims to convey that dormancy, as a whole, likely results from coalescing contributions made by each of the three types of dormancy discussed (cellular, angiogenic and immunological). In our opinion, dormancy-directed therapies will prove most effective when the effect of these cumulative contributions are understood and targeted.Keywords
This publication has 110 references indexed in Scilit:
- VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast ProgenitorsCancer Cell, 2011
- A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentThe Lancet Oncology, 2011
- Survivin and escaping in therapy‐induced cellular senescenceInternational Journal of Cancer, 2011
- B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cellsLeukemia Research, 2009
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- The Hallmarks of CancerCell, 2000
- Multistep Nature of Metastatic InefficiencyThe American Journal of Pathology, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889